FIELD: biotechnology.
SUBSTANCE: humanised anti-Gal9 monoclonal antibodies, as well as polynucleotides coding them, and expression vectors are disclosed. In addition, there are presented methods of using the anti-Gal9 antibodies for treating cancer, including a combination therapy with anti-PD-1/PD-L1 antibodies.
EFFECT: invention can find further application in cancer therapy.
42 cl, 15 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ISOLATED HUMAN CD45RC ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF, IN VITRO METHOD OF DETECTING hCD45RC | 2019 |
|
RU2826421C2 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| METHODS OF TREATING EYE CANCER USING ANTIBODIES TO MET AND BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MET | 2020 |
|
RU2830234C2 |
| NOVEL ANTIBODIES TO BSSL | 2020 |
|
RU2826992C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| SCLEROSTIN ANTIBODY, ITS ANTIGEN-BINDING FRAGMENT AND MEDICAL APPLICATION | 2016 |
|
RU2716101C2 |
| IL-4/IL-13 PATHWAY INHIBITORS FOR HIGHER EFFICACY IN TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2836467C2 |
| METHODS FOR TREATMENT OF SEVERE INSULIN RESISTANCE BY INTERRUPTING GLUCAGON RECEPTOR SIGNAL TRANSMISSION | 2017 |
|
RU2772508C2 |
